Merck/Schering’s Zetia/Zocor Combo Is Vytorin
This article was originally published in The Pink Sheet Daily
Merck and Schering-Plough have selected Vytorin as the brand name for the ezetimibe/simvastatin fixed-dose combination
You may also be interested in...
At least one of the active ingredients "must be new to the marketplace," a federal appeals court says in denying a patent extension for Abbott's Vicoprofen. The ruling could have a significant impact on big pharma companies that are eyeing combo therapies as growth drivers.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.